Alfonso Quintás-Cardama

Alfonso Quintás-Cardama

Chief Medical OfficeratFoghorn Therapeutics· In proxies 2022–2025

Pay in FY2025+47% from the year before · Foghorn Therapeutics stock +14.4% the same year

Alfonso Quintás-Cardama was paid $1.1M in FY2025 (Dec), up 47%. Foghorn Therapeutics stock rose 14.4% that year.

Pay$100 in the stock at the end of FY21 → $23
Pay is from the Summary Compensation Table of each Foghorn Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Foghorn TherapeuticsPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role -90%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?